Splanchnic, Portal, Pelvic, and Miscellaneous Venous Disorders

57.1Definition and presentation

Splanchnic, portal, and pelvic venous disorders encompass distinct anatomic territories with specific organ-threat profiles. Portal vein thrombosis (PVT) threatens portal inflow, variceal bleeding control, and access for future transjugular intrahepatic portosystemic shunt (TIPS) creation or liver transplantation EASL 2026 · AASLD 2020. Mesenteric venous thrombosis (MVT) threatens bowel viability and typically presents with acute abdominal pain; the development of peritonitis, sepsis, or acidosis indicates progression to intestinal infarction WSES 2022. Budd-Chiari syndrome represents hepatic venous or caval outflow obstruction and leads to congestive liver failure and portal-hypertensive decompensation APASL 2021. Pelvic venous disease encompasses reflux or obstructive pathophysiology that threatens physical function and quality of life, presenting with chronic pelvic pain, dyspareunia, dysmenorrhea, vulvar or perineal varices, and lower-extremity varices of pelvic origin Hanna 2024 · Meissner 2024.

Porto-sinusoidal vascular disease and non-cirrhotic portal hypertension cause portal-hypertensive complications, including variceal bleeding, ascites, and hepatic encephalopathy, despite preserved synthetic liver function. Approximately 40% of patients with porto-sinusoidal vascular disease develop PVT within 5 years Nicoara-Farcau 2020.

57.2Diagnosis and classification

Radiologic diagnosis of splanchnic thrombosis specifies the involved segments (main portal vein, right or left branches, splenic vein, superior or inferior mesenteric vein, hepatic veins, or inferior vena cava). Classification defines the acuity (recent versus chronic), extent (partial versus occlusive, cavernous transformation), and clinical context (cirrhotic, non-cirrhotic, malignant, inflammatory, or procedure-related) EASL 2026 · AASLD 2020 · Anticoagulation Forum 2016.

Pelvic venous disorders are characterized using the Symptoms-Varices-Pathophysiology (SVP) classification, which replaces syndromic labels such as pelvic congestion or May-Thurner syndrome Meissner 2021:

• Symptoms (S0 to S3): graded by pelvic and extrapelvic distribution.
• Varices (V0 to V3): defines the specific venous reservoir.
• Pathophysiology (P): identifies the anatomic location, hemodynamic mechanism (reflux or obstruction), and etiology (thrombotic, nonthrombotic, or congenital).

57.3Treatment thresholds and management logic

Management of splanchnic and pelvic venous disease targets the specific anatomic threat, balancing the prevention of venous extension against procedural and bleeding risks AASLD 2020 · Anticoagulation Forum 2016.

Stepwise clinical decision logic

1. Determine bowel viability in MVT. Immediate anticoagulation is the primary therapy for stable patients. Worsening pain, sepsis, acidosis, or peritoneal signs mandate operative exploration for bowel necrosis, removing the patient from the elective venous pathway WSES 2022.
2. Integrate PVT management with portal hypertension goals. In cirrhotic PVT, anticoagulation decisions are coordinated with endoscopic variceal management, decompressive strategy, and transplant access requirements AGA 2025 · Shanghai Consensus 2020. Anticoagulation is not automatic: observation with interval imaging is appropriate in selected chronic, minimally occlusive, or clinically stable non-progressive thrombosis, weighed against portal-hypertensive bleeding risk, while decompressive intervention is reserved for portal-hypertensive complications or transplant strategy.
3. Follow a stepwise approach for Budd-Chiari syndrome. Anticoagulation and liver-directed therapy are paired with initial recanalization of short segment obstructions. Shunting is reserved for un-recanalizable anatomy or severe portal decompensation APASL 2021 · Seijo 2013. Liver transplantation is the terminal salvage rung, reserved for failure of the stepwise sequence or fulminant hepatic failure.
4. Require symptom-hemodynamic correlation for pelvic disease. Pelvic embolisation or iliac stenting are indicated only when imaging findings match the patient's specific symptom complex; anatomic narrowing or dilated veins on cross-sectional imaging do not justify intervention in isolation Meissner 2024 · Meissner 2021.

57.4Medical therapy and anticoagulation

Intravenous unfractionated heparin or subcutaneous low-molecular-weight heparin is the first-line treatment for acute MVT without peritonitis, facilitating rapid reversal if surgery or procedures are required Acosta 2021 · Valeriani 2021. Long-term anticoagulation continues for at least 6 months following transient provoking factors, and is maintained indefinitely for idiopathic MVT or persistent thrombophilia.

Direct oral anticoagulants are indicated for selected patients with splanchnic vein thrombosis. They are avoided in the presence of advanced liver disease, severe renal dysfunction, high-risk bleeding, antiphospholipid syndrome, and in scenarios requiring rapid reversibility for procedural control AASLD 2020 · DOAC Meta-analysis 2023.

In cirrhotic PVT, early anticoagulation prevents thrombotic extension, promotes recanalization, and maintains feasibility for TIPS and liver transplantation Baveno VII 2022 · Shanghai Consensus 2020. Concurrent PSVD-associated PVT is managed with anticoagulation using the same principles applied to cirrhotic non-tumoral PVT Nicoara-Farcau 2020.

57.5Endovascular and surgical intervention

Endovascular escalation in superior mesenteric venous thrombosis is a rescue therapy for patients failing anticoagulation or experiencing progressive bowel threat. Thrombectomy, catheter-directed thrombolysis, and stent placement achieve technical success in 75% of selected patients with an 88.9% 14-day primary patency and an 82% 5-year survival Alnahhal 2022. Open bowel resection is required in 43.9% of acute MVT cases upon development of infarction; the 9.5% 30-day mortality reported in this series is the overall acute MVT figure, not the resection or transmural-infarction subgroup, whose mortality is higher Acosta 2021.

Budd-Chiari endovascular therapy achieves a 98.9% overall technical success rate and 96.9% clinical success rate Mukhiya 2022. Hepatic vein or inferior vena cava recanalization procedures demonstrate superior 5-year survival compared with TIPS or DIPS alone (97.9% versus 87.9%), establishing recanalization as the preferred initial intervention when technically feasible. The 5-year reintervention rate is 18.9%. In advanced or diffuse disease where direct recanalization cannot restore outflow, TIPS decompression is used; the hepatic venous pressure gradient is unreliable in Budd-Chiari because of the hepatic vein outflow block and is not used as the decision metric APASL 2021 · Seijo 2013.

Pelvic congestion embolotherapy yields a 94% technical success rate with consistent improvements in chronic pelvic pain, dyspareunia, and dysmenorrhea. Symptom recurrence occurs in 7.4% of patients and reintervention is required in 3.9%. The overall complication rate is 9.0%, and most events are minor Hanna 2024. Pelvic venous obstruction interventions are restricted to symptomatic patients; stents are not placed for asymptomatic anatomic narrowing, as embolisation alone underperforms when outflow obstruction is the dominant hemodynamic derangement Meissner 2024 · Iliac Stent Consensus 2024.

57.6Surveillance and follow-up

Following acute MVT, clinical reassessment and repeat imaging monitor for failure of anticoagulation to halt progression to bowel infarction Valeriani 2021. Long-term follow-up adjusts the duration of anticoagulation based on transient factors, persistent thrombophilia, malignancy, recurrent thrombosis, and liver disease trajectory Anticoagulation Forum 2016.

Post-procedural surveillance after Budd-Chiari reconstruction tracks restenosis, shunt dysfunction, progressive liver disease, and emergent portal-hypertensive complications, necessitating longitudinal care integrated with hepatology APASL 2021 · Seijo 2013.

Follow-up in pelvic venous disease evaluates symptom response rather than purely venographic occlusion. Efficacy is assessed against the presenting symptom domain, variceal reservoir, and concurrent gynaecologic or urologic diagnoses, directing staged treatments when mixed reflux and obstruction are identified Meissner 2024 · Meissner 2021.

57.7Areas of controversy

The superiority of hepatic vein recanalization over TIPS in Budd-Chiari syndrome relies on observational meta-analyses where selection bias directs recanalization toward less advanced disease Mukhiya 2022.

The efficacy of endovascular rescue therapy for superior mesenteric venous thrombosis is derived from small, retrospective, single-center series subject to significant selection bias, limiting its generalizability outside expert referral centers Alnahhal 2022.

Anticoagulation for concurrent PVT in porto-sinusoidal vascular disease lacks randomized trial data, and management is entirely extrapolated from practices in cirrhotic non-tumoral PVT Nicoara-Farcau 2020.

Direct oral anticoagulant applications in splanchnic vein thrombosis are supported by meta-analyses, but safety margins remain constrained by exclusions for advanced liver disease, bleeding risks, and drug interactions, precluding universal adoption DOAC Meta-analysis 2023.

Pelvic venous embolotherapy outcomes rely heavily on systematic reviews of observational data using varying symptom-response definitions and heterogeneous patient selection criteria Hanna 2024.